Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Setting the Stage: Qnexa and the Power of REMS

Mar 01 2012

• By Michael McCaughan

Related Content

FDA Standardizing REMS Re-Enrollment Procedures

Dec 02 2011

Just a Minute: The Final Step in Advisory Committee Process

Mar 01 2011

Regulatory Alchemy: The Transformative Power of the Opioid REMS

Jun 01 2011

The Qnexa Vote: Beyond the Bean Counting

Sep 01 2010

Weighing the Regulatory Climate: Qnexa and the New Approval Model

Sep 01 2010

FDA's Patient-Centered Drug Center

Dec 15 2011

Weighing the Risks: Vivus View of Regulatory Risks in <em>Qnexa</em> Reprise

Nov 20 2011

A Tale of Two Drugs: Meridia and Avandia, and the Issues that Separated Them

Nov 01 2010

Kaiser Pushes Back on REMS: Acorda Listens; Will FDA?

Feb 01 2010

REMS 2.0: FDA Refining New Drug Safety Tools

Dec 01 2010

Related Companies

Vivus, Inc.

GSK plc

Abbott

Arena Pharmaceuticals, Inc.

Orexigen Therapeutics, Inc.

Roche Holding AG

Additional Topics

Advisory Committees BioPharmaceutical

More from US FDA Performance Tracker

More from Regulatory Trackers

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window